VEGFR2-169

DB16152InvestigationalSmall molecule

VEGFR2-169 is under investigation in clinical trial NCT00655785 (Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)).

Mechanism: Pharmacologically active on MHC class I HLA-A protein
Curator reviewed
Formula / weight: C₄₇H₇₆N₁₆O₁₃ · 1073.224 g/mol (avg)
Also known as: Elpamotide · Vegfr2-169 peptide vaccine
Code names: VEGFR2-169

Resolves to

Compound

UNIIS68632MB2GCAS673478-49-4

Structure

InChIKeyZAJHBCDPAUKEPU-GIKXZWSFSA-NSMILES

CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCNC(N)=N)C(C)C)C(O)=O

Targets

P79603HLA-A*02

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with VEGFR2-169, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account